A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00409565 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Cancer
Squamous Cell Carcinoma

Interventions

DRUG: Cetuximab
DRUG: Bevacizumab

Sponsor

National Cancer Institute (NCI)